Glaukos Corporation
GKOS
NYSE49.91
Glaukos Corporation
NYSE:GKOS
RECENT
PRICE
49.91
P/E
RATIO
-26.52
(PEG:- -)
P/E RATIO
RELATIVE
TO S&P
-1.20
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
1.20 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 02/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
- -
- -
- -
- -
- -
- -
- -
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.84
(0.51)
(0.57)
- -
1.91
(0.51)
(0.33)
- -
4.10
(2.13)
(0.18)
- -
3.47
0.14
0.18
- -
4.63
(0.00)
0.56
- -
5.13
(0.37)
0.24
- -
6.34
0.41
(0.14)
- -
5.06
(2.70)
(0.67)
- -
6.29
(1.06)
(0.49)
- -
6.03
(1.90)
(1.38)
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.03
0.60
0.04
0.25
0.05
5.45
0.19
3.56
0.18
4.02
0.29
4.92
0.13
18.02
0.16
15.00
1.02
12.56
0.66
12.15
CAPEX per share
Book Value per share
- -
- -
- -
- -
- -
- -
- -
25
24
17
33
34
35
37
44
47
47
Comm.Shares outs.(m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(126.1)
(5.1)
- -
164.3
6.8
- -
(17.9)
(0.5)
- -
(65.0)
(2.2)
- -
(26.5)
(1.2)
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (30/9/22 | Q3)
Total liabilities
$460 m.
Total assets
$1,008 m.
Long-term debt
$383 m.
Cash and equiv.
$104 m.
Goodwill $66 m.
Retained earnings $(433) m.
Common stock 48 m. shares
Market Capitalisation
$2,381 m. (as of 7/2/23)
- -
- -
- -
- -
21
(67.8)%
46
(28.9)%
72
(14.4)%
114
3.7%
159
(1.4)%
181
(7.2)%
237
(21.2)%
225
(54.9)%
294
(11.2)%
285
(22.7)%
Revenue (m)
Operating margin
- -
- -
- -
- -
1
(13)
4
(12)
4
(37)
5
5
5
(0)
6
(13)
10
15
35
(120)
34
(50)
36
(90)
Depreciation (m)
Net profit (m)
- -
- -
- -
- -
(0.0)%
(60.3)%
(0.1)%
(26.6)%
(0.1)%
(51.9)%
0.9%
4.0%
9,300.0%
(0.1)%
(4.7)%
(7.1)%
130.8%
6.5%
9.0%
(53.5)%
(0.7)%
(16.9)%
1.7%
(30.8)%
Income tax rate
Net profit margin
- -
- -
- -
- -
- -
- -
6
18
15
(10)
9
6
84
1
95
103
- -
117
123
- -
138
146
- -
174
205
73
673
420
271
667
423
382
587
388
383
549
Working capital (m)
Long-term debt (m)
Equity (m)
- -
- -
- -
- -
- -
- -
(37.2)%
(31.9)%
(84.8)%
(72.8)%
(31.5)%
(199.4)%
(37.6)%
(31.0)%
(39.1)%
4.4%
3.8%
3.9%
(3.0)%
0.0%
(0.1)%
(7.3)%
(6.0)%
(7.4)%
1.9%
(5.8)%
2.3%
(11.2)%
(11.8)%
(18.0)%
(3.7)%
(3.4)%
(8.4)%
(7.9)%
(7.5)%
(16.3)%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
174
208
212
Receivables
38
36
33
Inventory
43
16
23
Other
8
13
16
Current assets
263
469
486
Acc. Payable
6
4
7
Debt due
- -
- -
- -
Other
52
45
56
Current liab.
58
50
63
- -
- -
- -
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
Plowback ratio
Div.&Repurch. to FCF
Glaukos Corporation (US) started trading on June 4, 2015 (cik: 0001192448), operates in the Healthcare sector (Medical Devices industry), has 727 full-time employees, and is led by Mr. Thomas Burns. Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
17.55%
- -
Cash flow
62.40%
- -
Earnings
3204.76%
- -
Dividends
- -
- -
Book value
75.04%
- -
Insider trading
Type
Shares
Date
Burns Thomas William
InKind
721
01/26/23
Burns Thomas William
InKind
1,802
01/26/23
Navratil Tomas
InKind
356
01/26/23
Navratil Tomas
InKind
885
01/26/23
Navratil Tomas
InKind
389
01/11/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
55
32
65
73
225
2021
68
78
75
73
294
2022
68
73
71
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
(1.21)
(0.90)
(0.35)
(0.24)
-2.70
2021
(0.35)
(0.37)
0.13
(0.47)
-1.06
2022
0.11
(0.96)
(0.58)
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -